Neuropep-1 ameliorates learning and memory deficits in an Alzheimer's disease mouse model, increases brain-derived neurotrophic factor expression in the brain, and causes reduction of amyloid beta plaques

Harpagoside ameliorates the amyloid-β-induced cognitive impairment in rats via up-regulating BDNF expression and MAPK/PI3K pathways

“…We observed that the expres-561 sion of BDNF significantly decreased in the hippocampus 562 in Ab-injected rats. Our result is in agreement with previ-563 ous studies showing decreased hippocampal BDNF con-564 tent in AD animal models(Li et al, 2009; Meng et al, 565 2013;Shin et al, 2014). Previous reports show that there 566 was a decrease in cortical BDNF protein or mRNA level 567 in vivo AD models(Christensen et al, 2008; Song et al, 568 2014).…”

The involvement of BDNF, NGF and GDNF in aging and Alzheimer's disease

“…Population studies have shown to date, a small sample size and this may be a weakness for these studies. Preclinical reports have investigated possible pharmacological treatments to increase BDNF levels in transgenic mice [51][52][53] or in animals subjected to administration of amyloid β peptide. Treatments with caffeine in AD transgenic animals shows increased levels of BDNF, and chronic treatments with caffeine improved both BDNF levels and cognitive impairment.…”

Oroxylin A enhances memory consolidation through the brain-derived neurotrophic factor in mice

“…Moreover, we and others have found that an increase of mature BDNF (mBDNF) in specific time period is crucial for its action on memory consolidation Kim et al, 2012). According to these findings, BDNF releasing agents or TrkB receptor agonists would be candidates for various brain disorders that show learning and memory disturbances (Shin et al, 2014;Zhang et al, 2014). Oroxylin A (5,7-dihydroxy-6-methoxyflavone) is a flavonoid compound isolated from the root of Scutellaria baicalensis Georgi.…”